A machine learning PET/CT model shows promise for predicting radiation dose prior to Lu-177 PSMA therapy in prostate cancer patients.
Key Details
- 1Study presented at SNMMI evaluated a machine learning model using F-18 PSMA PET/CT imaging.
- 2Nine patients with metastatic castration-resistant prostate cancer were included, analyzing a total of 57 tumors, 36 salivary glands, and 18 kidneys.
- 3The model used uptake-based PET metrics, radiomic features, and clinical biomarkers for dose prediction.
- 4Predictions closely tracked absorbed dose values obtained from traditional post-therapy dosimetry.
- 5Using pre-therapy PET/CT data could eliminate need for additional scans and reduce patient burden.
- 6The approach is part of a larger, ongoing 5-year research program for validation.
Why It Matters
This approach suggests standard diagnostic imaging can be repurposed with AI to deliver patient-specific radiation dose estimates before therapy, potentially improving safety, efficacy, and workflow efficiency in radiopharmaceutical therapy.
Source
AuntMinnie
Related News
•Radiology Business
Harrison.ai Restructures and Launches U.S. AI-Enabled Teleradiology Venture
Harrison.ai lays off staff amid major restructuring and launches Frontier Radiology, an AI-powered U.S. teleradiology business.
•Radiology Business
Healthcare Leader Warns AI Will Dominate Diagnostic Radiology
A leading oncologist urges future radiologists to specialize in interventional procedures due to AI advances in image interpretation.
•Radiology Business
UCLA Review Evaluates Breast AI for Early Cancer Detection
A UCLA-led review analyzes current evidence for AI tools in screening mammography, focusing on their capability to detect interval cancers.